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Colostrum and mature breast milk analysis of serum irisin and sterol
regulatory element-binding proteins-1c in gestational diabetes mellitus
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aDepartment of Biological and Biomedical Sciences, Aga Khan University, Karachi, Pakistan; bDepartment of Obstetrics and
Gynecology, Hamdard University, Karachi, Pakistan; cMedical College, Aga Khan University, Karachi, Pakistan; dUniversity of
Karachi, Karachi, Pakistan
Q1
ABSTRACT
Background: We aimed to evaluate irisin and SREBP-1c levels in serum, colostrum and mature
breast milk in women with and without gestational diabetes (GDM); and to relate them with
maternal glucose, lipid profile and weight status of babies.
Methods: GDM positive women (n¼ 33) and normal glucose tolerant women (NGT) (n¼ 33)
were recruited. Maternal blood samples were collected at 28th week of gestation and later at
6-week post-partum while breast milk samples of the lactating mothers were collected within
72hours of birth (colostrum) and at 6 weeks post-partum (mature milk). Irisin and SREBP-1c
levels were analyzed by commercially available ELISA kits for all maternal samples.
Results: Lower levels of irisin were seen in serum, colostrum and mature breast milk of GDM
females (p< .01). SREBP-1c profile showed a similar trend of low serum levels in GDM, however,
they were undetectable in colostrum and mature breast milk. Weak to moderate correlations of
serum irisin with BMI (r¼ 0.439; p< .001), GTT 0 hours (r¼ 0.403; p¼ .01), HbA1c (r¼0.312;
p¼ .011), Fasting blood glucose (r¼ 0.992; p¼ .008), and baby weight at birth (r¼ 0.486;
p< .001). Colostrum and mature breast milk irisin showed positive associations with baby weight
at 6 weeks (r¼ 0.325; p¼ .017; r¼ 0.296; p¼ .022, respectively). Serum SREBP-1c at 6 weeks cor-
related with the baby weight (r¼ 0.255; p¼ .039), random blood glucose (r¼ 0.318; p¼ .009),
and HbA1c (r¼0.292; p¼ .011). All correlations were lost once we adjusted for maternal BMI.
Conclusions: Low irisin and SREBP1-c levels may favor development of GDM in pregnant sub-
jects. Further, low mature breast milk levels may act as a continued stressor from fetal to infant
life as long as breast-feeding is continued. Further studies are required to identify the mechanis-
tic relationship between these biomarkers and GDM.
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Introduction
Gestational diabetes mellitus (GDM) is a growing pan-
demic in the world. At least 17.8% of women are being
affected by this condition worldwide [1]. GDM is often
accounted for by increased levels of maternal hormones
during pregnancy ensuring adequate energy supply to
the fetus like estrogen, progesterone, cortisol, human
chorionic gonadotrophin, and prolactin. These hor-
mones have been proven to work against insulin
thereby increasing its resistance [2]. The perinatal nutri-
tional environment is suggested to have a programing
effect on an individual’s susceptibility to develop obes-
ity [1]. Breastfeeding is suggested to be protective
against obesity which could partly be attributable to
bioactive compounds present in mature breast milk [3].
However, the specific components of mature breast
milk accounting for these effects have not yet been
identified. Since the discovery of the adipokines, many
strong candidates for the development of metabolic
syndrome (Mets) have been proposed [4].
Irisin is a recently discovered myokine which is
secreted into the serum by the skeletal muscles post
exercise [5,6]. Recent studies also show that low irisin
levels are characteristic of and may perhaps be a vital
factor contributing towards GDM. Irisin is involved in
the conversion of brown to white adipose tissue which
not only increase thermogenesis but also improves
glucose tolerance, insulin sensitivity, reductions in
body weight, decreased fat mass and reduced hepatic
triglyceride content [7,8]. Decreased levels of irisin
during pregnancy therefore may not only contribute
to GDM but also towards obesity owing to poor lipid
metabolism. Interestingly, some studies have reported
significantly decreased serum irisin levels in GDM
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pregnancies compared to normal pregnancies [9–12],
while others have reported little or no difference
between the two groups [13–15]. Nevertheless, none
fail to acknowledge the risks associated with GDM
during and postpregnancy for both the mother and
the child.
An important enzyme for the de novo lipid synthe-
sis principally expressed in lipogenic tissues is fatty
acid synthase (FAS) [16], and it is known to be
expressed in placenta [17]. This expression is in turn
controlled by “Sterol regulatory element-binding
proteins-1c” (SREBP1c) levels. It is observed that when-
ever there are a decreased cellular sterols and/or poly-
unsaturated fatty acid level; there is increase FAS gene
transcription via actions of SREBP-1c. Expression of
SREBP-1c is controlled by circulating hormones and
nutrients within the body [18]. Recent reports reveal
that in type II diabetes; the expression of SREBP-1c is
decreased as a consequence of impaired insulin signal-
ing. This will in turn cause irregular lipid synthesis
especially during pregnancy.
However, whether these biomarkers remain ele-
vated post-partum and released in mature breast milk
to cause a continuous supply for the baby remains to
be identified. Therefore, through this study we aim to
estimate the levels of irisin and SREBP-1c during preg-
nancy and in mature breast milk in lactating women
with and without GDM and relate them with maternal
lipid profile and weight gain of the newborn babies.
Materials and methods
This study recruited 66 pregnant women between the
ages of 20 and 35 years who visited the outpatient
clinic from July 2016 to August 2017 at the Taj
Medical Centre and Aga Khan University, Karachi. All
study subjects underwent an oral glucose tolerance
test at 24–28 weeks of gestation and were classified as
GDM (n¼ 33) or normal glucose tolerant women (NGT)
(n¼ 33) according to the International Association of
the Diabetes and Pregnancy Study (IADPSG) guidelines
[19]. The pregnant females were followed up from
24–28 weeks of gestation till 6 weeks’ postdelivery.
Pregnant subjects with preexisting diabetes, hyperten-
sion, twin pregnancies, and assisted pregnancies were
excluded from this study. After receiving ethical
approval from the institutional ethical review board
(Ref No. 4211-BBS-ERC-16) and written and informed
consent from all subjects, 5ml of maternal blood
samples were collected twice; first at 28th week of
gestation and again at 6 weeks post-partum.
Similarly, two breast milk samples of the lactating
mothers were collected; one within 72 hours of birth
(colostrum ¼3ml) and second at 6 weeks post-partum
(mature milk ¼10ml) with a manual breast pump. The
mothers were instructed to refrain from feeding for at
least 2 hours (8 am till 10 am) before collecting the
sample. These samples were aliquoted and were
stored in the dark at 80 C until analysis. For bio-
marker analysis, milk samples were pretreated accord-
ing to an established protocol [20]. Briefly, after
thawing at room temperature the samples were vor-
texed and sonicated three times for a 5-s burst. This
was followed by preparing skim milk by centrifugation
of whole milk at 14,000 rpm, for 30minutes at 4 C.
The resulting translucent sample was used for analysis.
All assays were carried out within 2 months of storage.
Irisin and SREBP-1c levels were analyzed by commer-
cially available ELISA kit (Kit Cat number 95512 and
F9350, Glory Science Co Ltd) Q5.
Additionally, a spike-and-recovery experiment was
designed to assess the difference in assay response
according to a set protocol [21]. Briefly, the following
procedure and samples were used (i) sample diluent
serving as blank, (ii) sample diluent spiked with known
concentration of standard (to allow quantification of
exogenous analyte), (iii) Two breast milk analytes
without spiking (to allow quantification of endogenous
analyte), (iv) Two breast milk analytes spiked with
known concentration of standard (to allow quantifica-
tion of both exogenous and endogenous analyte). Ten
microliters of spike stock solution was added to the
samples, calculated to yield 240 pg/ml spike concentra-
tion. Values used for breast milk spiked samples reflect
subtraction of the endogenous (no-spike) sample
value. The samples were run in duplicates and a mean
score was used. The recovery rate for all samples was
between 93 and 98% with intra-assay and interassay
coefficients of variation <10% and <15%, respectively.
A range between 80 and 120% recovery is considered
acceptable for such experiments [22].
Weight of mothers was assessed at the time of first
visit (i.e. 12–15 weeks of gestation), at the time of
glucose tolerance test, i.e. 28 weeks of gestation and
at 6 weeks’ post-partum. Body mass index (BMI) was
calculated by dividing weight by height squared
(kg/m2). South Asian reference range for BMI was used
to categorize study subjects [23]. Clinical data includ-
ing maternal age, height, family history of diabetes
mellitus, gender, and weight of newborn were
recorded from the patient record card.
Statistical analysis
Statistical analyses were conducted using the IBM
Statistical Package for the Social Sciences (IBM SPSS
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version 21; IBM Corp Inc, Armonk, NY, USA). Descriptive
analysis of categorical data was presented in terms of
frequencies and percentages, whereas that for
continuous variables was expressed as mean± standard
deviation. Continuous variables were assessed by
Mann–Whitney U test. Spearman’s correlation between
serum irisin, SREBP-1c and clinical parameters were also
calculated. p value <.05 were regarded to be significant.
Results
The results are displayed in Tables 1–2. The study sub-
jects were aged matched therefore we did not find
any difference. Females with GDM had a higher body
weight, fasting blood glucose (FBG), and random
blood glucose (RBG) at 6 weeks postpartum (p< .01).
Interestingly, the HbA1c levels at follow up were
within normal range for the GDM subjects. The new-
born data showed that babies of GDM positive moth-
ers had a higher weight by scan at 28 weeks of
gestation, at birth and at follow up 6 weeks after birth
(Table 1).
Table 2 shows the biomarker levels in the study
subjects. We observed a low serum irisin level in GDM
females at 28, 6 weeks postpartum compared to
normo-glycemic females (p< .01). Similarly, colostrum
and mature breast milk irisin was also low in GDM
subjects. SREBP1-c profile showed a similar trend of
low serum levels in GDM, however, these levels
reduced from a very low value to undetectable range
in colostrum and mature breast milk respectively.
However, we found no differences in the lipid profile
post pregnancy in the study cohort. Furthermore, we
found weak to moderate correlations of Serum irisin
with BMI (r¼ 0.439; p> .001) GTT 0 hours (r¼ 0.403;
p¼ .01), HbA1c (r¼0.312; r¼.011), FBG (r¼ 0.992;
p¼ .008) and baby weight at birth (r¼ 0.486; p< .001).
Colostrum and mature breast milk irisin showed
positive associations with baby weight at 6 weeks
(r¼ 0.325; p¼ .017; r¼ 0.296; p¼ .022, respectively).
Serum SREBP-1c at 6 weeks correlated with the baby
weight at 6 weeks (r¼ 0.255; p¼ .039), RBG at 6 weeks
(r¼ 0.318; p¼ .009), and HbA1c (r¼0.292; p¼ .011).
However all correlations were lost once we adjusted
for maternal BMI. Therefore, these associations were
dependent on the maternal weight and BMI.
Discussion
The finding of our study showed lower levels of irisin
in serum, colostrum and mature breast milk of GDM
females. These low levels may increase the risk of
developing diabetes mellitus type 2, hypoglycaemia,
and respiratory distress syndrome [10,11]. Contrary to
our finding, one study found irisin levels to increase
from colostrum to transitional and mature milk in both
normal glucose tolerant and GDM patients [10]. Low
irisin levels in the serum, mature breast milk and
colostrum acts as a continued stressor from fetal to
infant life. This may continue to have adverse effects
on the baby’s health and lipid regulation as long as
breast-feeding is continued. Irisin has proven to play a
vital role in improving obesity and glucose homeosta-
sis. It has been proposed that irisin increases adeno-
sine monophosphate (AMP) activated protein kinase
phosphorylation and increases glucose uptake; there-
fore plays an important role in glucose metabolism
[24]. Irisin further has proven to inhibit atherosclerosis
by endothelial proliferation [25], cholesterol synthesis
in the hepatocytes [26] and promote osteoblast prolif-
eration and differentiation [27]. Therefore, we believe
that low irisin in the GDM population may have crucial
effects on the mother’s and baby’s health, both during
pregnancy and post-partum. It is also postulated that
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Table 1. Maternal and newborn data.
NGT
n¼ 33
GDM
n¼ 33
Variables Mean ± SD Mean ± SD p value
Maternal data
Age (year) 24.10 ± 1.77 24.23 ± 1.14 .412
BMI (kg/m2) 20.55 ± 3.76 25.22 ± 4.24 <.001
GTT at 0 hours 78.24 ± 12.05 103.27 ± 15.15 <.001
GTT at 2 hours 120.48 ± 10.47 162.66 ± 44.68 <.001
RBG 6 weeks postpartum (mg/dl) 107.04 ± 19.45 144.00 ± 3.66Q3 <.001
HbA1c 6 weeks post-partum (mg/dl) NA 5.23 ± 0.92 –
New-born data
Abdominal circumference by scan (cm) at 28 weeks of gestation 26.80 ± 3.98 28.51 ± 5.09 .135
Foetal weight by scan (kg) at 28 weeks of gestation 1.98 ± 0.54 2.28 ± 0.59 .008
Baby gender Male 19 (57.57) Male 16 (48.48) .547
Female 14 (42.42) Female 17 (51.51)
Baby weight at birth (kg) 3.53 ± 0.51 4.41 ± 0.97 <.001
Baby weight at 6 weeks (kg) 4.35 ± 0.40 5.53 ± 0.15 <.001
BMI: body mass index; RBG: random blood glucose. Values expressed as mean and standard deviation and absolute number
with percentage in parenthesis.
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the levels affect intrauterine growth of the fetus.
However recent studies by Briana and group [28]
reported that no difference was observed in cord
blood levels of intra uterine growth retardation and
normal for gestational age babies. Similarly they
reported that irisin levels decrease with advancing ges-
tational weeks and this could be attributed to
increased maternal fat deposition. That may lead to
insulin resistance in the latter half of pregnancy [29].
These findings strongly support our hypothesis and
results. As of late, no validated normal range for irisin
have been reported, but low serum irisin levels were
reported in Japanese population (1.1 ± 0.1 ng/ml for
males and 1.2 ± 0.2 ng/ml for females) [30] and in
Tehran, Iran (0.81 ± 0.41 ng/ml in normal weight obese
and 0.58 ± 0.26 ng/ml controls) [31]. Perhaps these
differences in irisin levels are observed due to interpo-
pulation or plasma versus serum sample differences,
yet our results are quite similar to the neighbor-
ing countries.
Increased levels of FBG/RBG at 6 weeks post-partum
were seen in our study. Similar to our findings, a posi-
tive association between GDM history, 2-hour glucose;
and HbA1c during pregnancy and post-partum diabetes
was seen within Chinese women [32]. Interestingly, in a
recent study conducted by our group, we found that
14% of GDM positive females developed DM within 2
years of their last pregnancies [33]. Furthermore, we
report a higher birth weight as well as infant weight 6
weeks post birth for GDM mothers. The incidence of
fetal macrosomia ranges between 20 and 40% in GDM
positive cases [34], but the baby weight normalizes
with time [35]. However, our findings suggests that the
constant stress in terms of low irisin though mature
breast milk was a trigger for the deranged body fat
accumulation and higher body weight of these infants.
We also report a significantly lower level of SREBP-
1c in serum and colostrum of GDM positive females
however, its level was undetectable in the mature
breast milk of both the groups. Further we did not
find any differences in maternal lipid profile among
the groups. This may be due to the fact that GDM
increases concentration of inflammatory cytokines
which induces fatty acid synthase (FAS) expression but
not the expression of SREBP protein [36]. A study
found significant increase in expression of SREBP-2
and fatty acid synthase (FAS) in the placenta while
both 3-hydroxy-3-methylglutaryl-CoA (HMG Co-A) lyase
and SREBP-1 were not modified. Supposedly, in GDM
as irisin levels tend to decrease, insulin resistance tend
to increase which in turn may effect levels of SREBP-1
[37]. Since SREBP proteins are responsible for uptake
and synthesis of fatty acids and cholesterol [38], our
hypothesis suggested that there should be higher lev-
els of lipid biomarkers in the maternal serum. Yet, no
significant difference was observed in the lipid profile
of GDM and non-GDM mothers. We assume that since
the GDM inflicted mothers were kept on diet and drug
regimens, that may have contributed to the within
normal range levels as seen.
Lastly, we report a weak to moderate correlation of
irisin with maternal BMI, GTT, baby weight at birth, and
FBG. In addition, colostrum and mature breast milk iri-
sin showed positive associations with baby weight at 6
weeks. However, all correlations were lost once we
adjusted for maternal BMI. Therefore, we believe that
these associations were dependent on the maternal
weight and BMI. A similar finding was reported that iri-
sin was positively related with BMI and FBG [39], yet
another study reported that none of the anthropomet-
ric parameters to correlate with serum irisin levels [40].
Another study’s findings suggested that irisin was
negatively correlated with age and FBG while positively
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Table 2. Maternal serum, colostrum, and mature breast milk biomarker data.
NGT
n¼ 33
GDM
n¼ 33
Variables Mean ± SD Mean ± SD p Value
Irisin profile
Serum Irisin at 28-week gestation (pg/ml) 72.94 ± 9.11 42.09 ± 3.21 .01
Serum Irisin at 6 weeks post-partum (pg/ml) 264.97 ± 40.88 138.32 ± 6.82 .003
Colostrum Irisin (pg/ml) 57.08 ± 8.28 10.36 ± 4.73 <.001
Mature breast milk Irisin (pg/ml) 56.40 ± 9.55 15.35 ± 0.42 <.001
SREBP-1c profile
Serum SREBP1-c at 28-week gestation (pg/ml) 73.94 ± 9.41 43.62 ± 7.33 .013
Serum SREBP1-c at 6 post-partum (pg/ml) 38.33 ± 1.752 20.92 ± 1.755 < .001
Colostrum SREBP1-c (pg/ml) 9.39 ± 4.07 4.09 ± 1.65 .233
Mature breast milk SREBP1-c (pg/ml) 0.00 0.00 –
Lipid profile at 6 weeks post-partum
Cholesterol (mg/dl) 187.66 ± 31.50 172.84 ± 44.03 .518
TAG (mg/dl) 133.09 ± 17.97 147. ± 11.00 .340
HDL (mg/dl) 45.72 ± 9.40 47.66 ± 8.20 .612
LDL (mg/dl) 107.56 ± 3.69 113.73 ± 5.10 .584
Values expressed as mean and standard deviation.
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correlated with HDL-c [41]. Interestingly, Sinanoglu and
group [40] proposed an ethnicity and maternal age
related link with the fat content of colostrum instead of
the commonly agreed notion of maternal pre preg-
nancy BMI. They also suggest that this finding can
be used to design custom diets for mothers to
enhance the mature breast milk nutritional value and in
turn have a positive impact on new born health.
Furthermore, another recent study measured irisin lev-
els in babies and compared them with growth rate and
insulin levels. They report that low irisin levels were
seen in intra uterine growth restricted babies and irisin
showed a weak positive correlation with the birth
weight of babies. In addition, a weak positive associ-
ation was also seen for fetal irisin and insulin concentra-
tions [42].
We postulate that derangement of both irisin and
SREBP in pregnancy may be trigger abnormal fatty acid
(FA) metabolism. Furthermore, impaired metabolism
causes accumulation of reactive lipid species eventually
altering the response to tissue insulin signaling. Irisin
may induce gene expression changes by directly acting
on the tissues or indirectly by inducing a “factor X”.
This has significant implication for irisin as a novel
therapeutic target. However, further mechanistic
research is required to validate and propose this effect.
Furthermore, in addition to being secreted from
skeletal and cardiac muscle, irisin has also been
detected in the brain (neurons and neuroglia), the skin
(sebaceous glands), the testis, epididymis, liver, pan-
creas, spleen, stomach, and three major paired salivary
glands (submandibular, sublingual, and parotid)
[43–45]. It is removed from the body mainly through
the hepato-biliary system and the kidneys [45–47]. It is
possible that these molecules may act as trophic or
mediating agents that sends signal to brain, gut,
muscle, and adipose tissue during pregnancy or via
breast milk post-partum. Therefore, it is plausible to
comment that irisin may modulate energy expenditure
or food intake through topical, paracrine or autocrine
actions. This could potentially have postnatal effects
on the baby via skin, tongue or gut to modify energy
metabolism and stimulate appetite center in brain, tis-
sue hyperplasia or hypertrophy in adipose tissue and
liver [48–50]. The exact focal mechanism or function
however is currently unknown, so future in vivo studies
are required that might provide the conclusive results
to consolidate this hypothesis.
Conclusions
Low irisin and SREBP-1c levels in the serum, mature
breast milk and colostrum may favor development of
GDM in pregnant subjects. Further, low mature breast
milk irisin and SREBP-1c levels may act as a continued
stressor from fetal to infant life till breast-feeding is
continued. Further studies are required to identify the
mechanistic relationship between these biomarkers
and GDM.
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